Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 12F capsular polysaccharide antigen
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a highly purified component derived from the capsule of Streptococcus pneumoniae serotype 12F. It is used as an active immunization agent, either alone or as part of multivalent pneumococcal vaccines, to prevent diseases such as pneumococcal pneumonia and bacteremia. The mechanism of action involves stimulating the immune system to produce antibodies against the serotype-specific capsule, thereby providing protection against invasive disease caused by S. pneumoniae serotype 12F. This antigen is included in both unconjugated (polysaccharide) and conjugate vaccine formulations, such as PPSV23 (Pneumovax 23) and PCV20/PCV21 (Prevnar/Vaxneuvance/CAPVAXIVE), which are approved for use in adults and sometimes children for prevention of invasive pneumococcal disease[3][6][7].
- Brand names
- Pneumovax 23Pneumovax23Pneumovax-23Prevnar 20Prevnar20Prevnar-20
- Other names
- streptococcus pneumoniae type 12f capsular polysaccharide antigen
02
Targets
12F CPS (Streptococcus pneumoniae serotype 12F capsular polysaccharide)
Beyond the preview
Go deeper on Streptococcus pneumoniae type 12F capsular polysaccharide antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 12F capsular polysaccharide antigen.